This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The portfolio includes branded injectable cephalosporines for infectious diseases
The company expects to launch this product through its marketing partner in the near future
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Awards highlight Avantor's commitment to the Biopharma industry
Subscribe To Our Newsletter & Stay Updated